Gleason Group’s Aptose Biosciences, Inc. APTO Stock Holding History

Gleason Group’s Portfolio APTO Stock Details APTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.34K	Hold	4,206	–	–	﹤0.01%	285
2026 Q1	$7.02K	Hold	4,206	–	–	﹤0.01%	191
2025 Q4	$6.5K	Hold	4,206	–	–	﹤0.01%	190
2025 Q3	$4.96K	Hold	4,206	–	–	﹤0.01%	175
2025 Q2	$3.55K	Buy	4,206 +4,166	+10,415%	+$7.12K	﹤0.01%	184
2025 Q1	$126	Sell	40 -1	-2%	-$5	﹤0.01%	187
2024 Q4	$274	Hold	41	–	–	﹤0.01%	190
2024 Q3	$500	Hold	41	–	–	﹤0.01%	185
2024 Q2	$923	Hold	41	–	–	﹤0.01%	262
2024 Q1	$2.02K	Hold	41	–	–	﹤0.01%	191
2023 Q4	$3.09K	Hold	41	–	–	﹤0.01%	200
2023 Q3	$3.4K	Hold	41	–	–	﹤0.01%	205
2023 Q2	$5.64K	Hold	41	–	–	﹤0.01%	199
2023 Q1	$11.7K	Hold	41	–	–	﹤0.01%	170
2022 Q4	$10.6K	Hold	41	–	–	﹤0.01%	169
2022 Q3	$11K	Hold	41	–	–	﹤0.01%	171
2022 Q2	$14K	Hold	41	–	–	﹤0.01%	162
2022 Q1	$25K	Buy	+41	New	+$22.7K	0.01%	143

Other funds holding APTO

DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return

CSC

Caldwell Sutter Capital Sausalito, California $265M AUM 30.15% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Gleason Group's APTO Position: Q2 2026 in Review

Gleason Group held its Aptose Biosciences, Inc. (APTO) position steady in Q2 2026 at 4,206 shares worth $6.34K. The position accounts for ﹤0.01% of the portfolio, ranked #285.

Gleason Group first reported a position in APTO in Q1 2022 and has held it in 18 quarters since. The position peaked at $25K in Q1 2022. 4 funds tracked by Wall St. Rank hold APTO as of Q2 2026.

Gleason Group held 4,206 shares of Aptose Biosciences, Inc. worth $6.34K as of Q2 2026.
Gleason Group left its Aptose Biosciences, Inc. share count unchanged in Q2 2026.
Aptose Biosciences, Inc. made up ﹤0.01% of Gleason Group's portfolio in Q2 2026, its #285 holding.
Gleason Group first reported a position in Aptose Biosciences, Inc. in Q1 2022 and has held it in 18 quarters since.
Gleason Group's Aptose Biosciences, Inc. position peaked at $25K in Q1 2022.
4 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2026.

Based on Gleason Group's 13F filing for Q2 2026, filed 13 Jul 2026.